EP0648265A4 - Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure. - Google Patents
Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure.Info
- Publication number
- EP0648265A4 EP0648265A4 EP93915422A EP93915422A EP0648265A4 EP 0648265 A4 EP0648265 A4 EP 0648265A4 EP 93915422 A EP93915422 A EP 93915422A EP 93915422 A EP93915422 A EP 93915422A EP 0648265 A4 EP0648265 A4 EP 0648265A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- transgenic non
- human animals
- artificial chromosome
- yeast artificial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000009261 transgenic effect Effects 0.000 title abstract 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 title 1
- 108700019146 Transgenes Proteins 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 101100268553 Homo sapiens APP gene Proteins 0.000 abstract 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 238000001638 lipofection Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1493 | 1979-01-08 | ||
US90097292A | 1992-06-18 | 1992-06-18 | |
US900972 | 1992-06-18 | ||
US149393A | 1993-01-07 | 1993-01-07 | |
PCT/US1993/005873 WO1994000569A1 (fr) | 1992-06-18 | 1993-06-18 | Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0648265A1 EP0648265A1 (fr) | 1995-04-19 |
EP0648265A4 true EP0648265A4 (fr) | 1996-12-04 |
Family
ID=26669098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93915422A Withdrawn EP0648265A4 (fr) | 1992-06-18 | 1993-06-18 | Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure. |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0648265A4 (fr) |
JP (1) | JPH07508410A (fr) |
AU (1) | AU4541093A (fr) |
CA (1) | CA2135313A1 (fr) |
NZ (1) | NZ253943A (fr) |
WO (1) | WO1994000569A1 (fr) |
Families Citing this family (238)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) * | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
JPH07509137A (ja) * | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
WO1994023049A2 (fr) * | 1993-04-02 | 1994-10-13 | The Johns Hopkins University | Introduction et expression de grandes sequences genomiques chez des animaux transgeniques |
PT730643E (pt) | 1993-10-27 | 2001-06-29 | Lilly Co Eli | Animais transgenicos portadores do alelo de app com mutacao sueca |
FR2714830B1 (fr) * | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
FR2732895B1 (fr) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament |
KR20050085971A (ko) * | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
US6210919B1 (en) | 1995-04-28 | 2001-04-03 | Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US6531586B1 (en) | 1995-04-28 | 2003-03-11 | The Hospital For Sick Children | Genetic sequences related to Alzheimer's Disease |
CA2223088A1 (fr) | 1995-06-07 | 1996-12-19 | Bob Dale Brown | Nouveaux lipides cationiques a base de carbamate |
US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
JP2000506375A (ja) * | 1996-01-26 | 2000-05-30 | エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ | アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用 |
US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
CA2183901A1 (fr) * | 1996-08-22 | 1998-02-23 | Johanna E. Bergmann | Cibles pour le traitement et le diagnostic de la maladie d'alzheimer et du syndrome de down chez les humains |
EP2314625B1 (fr) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Mammifères transgèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EA006972B1 (ru) | 1998-12-23 | 2006-06-30 | Пфайзер Инк. | Моноклональное антитело человека к ctla-4 и способы его применения |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US6900367B2 (en) | 2000-09-29 | 2005-05-31 | Novartis | Transgenic Drosophila melanogaster expressing a β42 in the eye |
JP2004532205A (ja) * | 2001-03-22 | 2004-10-21 | クロモス・モレキユラー・システムズ・インコーポレーテツド | 細胞への核酸分子の送達およびその評価方法 |
IL157746A0 (en) * | 2001-05-30 | 2004-03-28 | Chromos Molecular Systems Inc | Chromosome-based platforms |
AU2003213271B2 (en) | 2002-02-25 | 2009-07-16 | Genentech, Inc. | Novel type-1 cytokine receptor GLM-R |
WO2004050683A2 (fr) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation |
EP2239329A1 (fr) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions thérapeutiques |
EP3000886A1 (fr) | 2003-03-19 | 2016-03-30 | Amgen Fremont Inc. | Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations |
EP2669377A3 (fr) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Agents iARN modifiés |
BRPI0411803A (pt) | 2003-06-27 | 2006-05-23 | Abgenix Inc | anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos |
MXPA06001353A (es) | 2003-08-08 | 2006-05-04 | Abgenix Inc | Anticuerpos dirigidos a hormona paratiroides(pth) y usos de los mismos. |
CN1274814C (zh) * | 2003-09-23 | 2006-09-13 | 李宁 | 一种提高转基因动物生产效率的方法 |
AU2005227313A1 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through V gene manipulation |
EP2287195B1 (fr) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Anticorps contre le Pan-KIR2DL NK-recepteur et leur utilsation diagnostique at therapeutique |
NZ554824A (en) | 2004-10-22 | 2010-10-29 | Revivicor Inc | Porcines that lack endogenous antibody chains and express exogenous immunoglobulins |
US20080026457A1 (en) | 2004-10-22 | 2008-01-31 | Kevin Wells | Ungulates with genetically modified immune systems |
EP1824886B1 (fr) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Anticorps monoclonaux entierement humains diriges contre l'il-13 |
US7572444B2 (en) | 2004-12-20 | 2009-08-11 | Amgen Fremont Inc. | Binding proteins specific for human matriptase |
CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
CA2590164A1 (fr) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Anticorps diriges contre interleukine-1 beta |
EP1957115B8 (fr) | 2005-11-10 | 2014-03-05 | Celldex Therapeutics, Inc. | Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1) |
EP1979001B1 (fr) | 2005-12-13 | 2012-04-11 | Medimmune Limited | Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
DK2463305T3 (en) | 2006-01-12 | 2016-08-29 | Alexion Pharma Inc | Antibodies to OX-2 / CD200 and uses thereof |
WO2007118214A2 (fr) | 2006-04-07 | 2007-10-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions d'anticorps et méthodes de traitement d'une maladie néoplasique |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
ES2746925T3 (es) | 2006-08-03 | 2020-03-09 | Medimmune Ltd | Anticuerpos dirigidos hacia alfaVbeta6 y uso de los mismos |
GEP20146112B (en) | 2007-03-22 | 2014-06-25 | Ucb Pharma Sa | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof |
DK2185719T3 (en) | 2007-08-02 | 2014-02-17 | Novimmune Sa | ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF |
EP4248976A3 (fr) | 2007-08-23 | 2024-04-10 | Amgen Inc. | Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (pcsk9) |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
SG187477A1 (en) | 2007-09-26 | 2013-02-28 | U3 Pharma Gmbh | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
CN103275227B (zh) | 2007-11-12 | 2015-02-11 | U3制药有限公司 | Axl抗体 |
CA2910760C (fr) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Lipides de ciblage |
WO2009126933A2 (fr) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Délivrance spécifique à un site d'acides nucléiques en combinant des ligands de ciblage avec des composants endosomolytiques |
WO2010032060A1 (fr) | 2008-09-19 | 2010-03-25 | Medimmune Llc | Anticorps dirigés contre dll4 et leurs utilisations |
EP2348827B1 (fr) | 2008-10-27 | 2015-07-01 | Revivicor, Inc. | Ongulés immunodéprimés |
ES2940466T3 (es) | 2008-11-10 | 2023-05-08 | Alexion Pharma Inc | Métodos y composiciones para tratar trastornos asociados al complemento |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
WO2011057250A1 (fr) | 2009-11-09 | 2011-05-12 | Alexion Pharmaceuticals, Inc. | Réactifs et procédés destinés à détecter des globules blancs associés à une hpn de type ii et leur identification comme facteurs de risque pour des troubles thrombotiques |
CN102812045B (zh) | 2009-11-13 | 2018-04-13 | 第一三共欧洲有限公司 | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 |
MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
JP6012473B2 (ja) | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
WO2011109427A2 (fr) | 2010-03-01 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Amélioration de l'activité biologique de parni par modulation de son profil thermodynamique |
SG185383A1 (en) | 2010-04-30 | 2012-12-28 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
KR20130036276A (ko) | 2010-06-22 | 2013-04-11 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 보체 결합 3의 C3d 조각에 대한 항체들 |
CA2815154A1 (fr) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Utilisation d'agents de liaison her3 dans le traitement de la prostate |
SG192047A1 (en) | 2011-01-24 | 2013-08-30 | Univ Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
US9447187B2 (en) | 2011-02-03 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
CA2831957A1 (fr) | 2011-04-07 | 2012-10-11 | Amgen Inc. | Nouvelles proteines de liaison d'egfr |
WO2012142164A1 (fr) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps monoclonaux humains qui se lient aux facteurs de croissance insulinomimétique (igf) de type i et ii |
JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
CN103842383B (zh) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | 多特异性fab融合蛋白及其使用方法 |
CN112961855A (zh) | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法 |
US9156911B2 (en) | 2011-07-18 | 2015-10-13 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
WO2013067055A1 (fr) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Procédés de blocage de la croissance des cellules souches cancéreuses |
EP2773667A1 (fr) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anticorps anti-gpr49 |
EP2773665A1 (fr) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anticorps et procédés de traitement du cancer |
EP2773664A1 (fr) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anticorps anti-gpr49 |
KR20140091064A (ko) | 2011-11-16 | 2014-07-18 | 암젠 인크 | 표피 성장 인자 결실 돌연변이체 vⅲ 관련 장애를 치료하는 방법 |
SI3301177T1 (sl) | 2011-11-18 | 2020-07-31 | Alnylam Pharmaceuticals, Inc. | Sredstva RNAi, sestavki in postopki njihove uporabe za zdravljenje s transtiretinom (TTR) povezanih bolezni |
US9796974B2 (en) | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
DK2812443T3 (da) | 2012-02-06 | 2019-08-26 | Inhibrx Inc | Cd47-antistoffer og fremgangsmåder til anvendelse deraf |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
BR112014031028A2 (pt) | 2012-06-11 | 2017-08-15 | Amgen Inc | Proteína de ligação ao antígeno isolado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para produzir uma proteína de ligação ao antígeno, composição, método para reduzir ou bloquear a atividade de miostatina, activin a ou gdf-11, método para aumentar a firmeza da massa muscular ou aumentar a proporção da firmeza da massa muscular para massa adiposo em um indivíduo necessitado do referido tratamento, método para tratar ou prevenir uma doença prejudicial do músculo em um indivíduo sofrendo do referido distúrbio e anticorpo receptor duplo antagonista |
WO2014022739A2 (fr) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Agents constitués d'arni modifié |
HUE035887T2 (en) | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
EP2948478B1 (fr) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Anticorps ciblant cdh19 pour un mélanome |
SG10201706383XA (en) | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
CN114015692A (zh) | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | 补体组分C5 iRNA组合物及其使用方法 |
ES2753950T3 (es) | 2013-03-15 | 2020-04-15 | Amgen Res Munich Gmbh | Moléculas de unión monocatenarias que comprenden ABP del extremo N |
US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
CN105408481B (zh) | 2013-05-22 | 2021-03-30 | 阿尔尼拉姆医药品有限公司 | SERPINA1 iRNA组合物及其使用方法 |
TW202342750A (zh) | 2013-05-22 | 2023-11-01 | 美商阿尼拉製藥公司 | TMPRSS6 iRNA組成物及其使用方法 |
JP6267792B2 (ja) | 2013-06-28 | 2018-01-24 | アムジエン・インコーポレーテツド | ホモ接合性家族性高コレステロール血症の治療方法 |
US10077304B2 (en) | 2013-08-14 | 2018-09-18 | The Governing Council Of The University Of Toronto | Antibodies against frizzled receptor |
TW201610151A (zh) | 2013-09-23 | 2016-03-16 | 阿尼拉製藥公司 | 治療或預防與甲狀腺素運載蛋白相關疾病之方法 |
CN105814205B (zh) | 2013-12-12 | 2019-11-19 | 阿尔尼拉姆医药品有限公司 | 补体成分iRNA组合物及其使用方法 |
WO2015106128A2 (fr) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | Agents d'arni modifiés |
WO2015123264A1 (fr) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de cétohexokinase (khk) et procédés pour les utiliser |
MX2016012873A (es) | 2014-04-04 | 2017-03-07 | Bionomics Inc | Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5). |
EP3146049B1 (fr) | 2014-05-22 | 2020-02-26 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni produisant un effet sur l'angiotensinogène (agt) et leurs procédés d'utilisation |
TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
WO2016016859A1 (fr) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Constructions optimisées d'anticorps monocaténaires, bispécifiques, spécifiques d'espèces croisées |
TW201609811A (zh) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | 具有增強之組織分布之雙特異性單鏈抗體構築體 |
KR102494171B1 (ko) | 2014-08-20 | 2023-02-02 | 알닐람 파마슈티칼스 인코포레이티드 | 변형 이중-가닥 rna 제제 |
WO2016040589A1 (fr) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation |
JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
EP3207138B1 (fr) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Agents polynucléotidiques de ciblage d'acide aminolévulinique synthase-1 (alas1) et utilisations de ceux-ci |
WO2016069694A2 (fr) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Agents polynucléotidiques ciblant serpinc 1 (at3) et leurs méthodes d'utilisation |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
WO2016081444A1 (fr) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni d'apolipoprotéine c3 (apoc3) et procédés d'utilisation de ces compositions |
WO2016130806A2 (fr) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du gène codant pour la protéine 3 contenant un domaine phospholipase de type patatine (pnpla3) et leurs procédés d'utilisation |
MX2017012610A (es) | 2015-04-08 | 2018-03-16 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen lect2. |
HUE061730T2 (hu) | 2015-04-17 | 2023-08-28 | Amgen Res Munich Gmbh | Bispecifikus antitest-konstrukciók CDH3-hoz és CD3-hoz |
EP3292201A2 (fr) | 2015-05-06 | 2018-03-14 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de facteur xii (facteur hageman) (f12), de la kallicréine b plasmatique (facteur fletcher) 1 (klkb1) et de kininogène 1 (kng1) et procédés d'utilisation associés |
WO2016201301A1 (fr) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de composant du complément c5 et leurs procédés d'utilisation |
EP3310918B1 (fr) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Agents polynucléotidiques ciblant l'hydroxyacide oxydase (glycolate oxydase, hao1) et procédés d'utilisation de ceux-ci |
WO2016209862A1 (fr) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Compositions d'arndb contre un gène de glucokinase (gck) et leurs procédés d'utilisation |
US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
WO2017040078A1 (fr) | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni ciblant le ligand de mort cellulaire programmée 1 (pd-l1) et leurs méthodes d'utilisation |
WO2017048620A1 (fr) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Agents de polynucléotide ciblant un domaine de phospholipase de type patatine contenant 3 (pnpla3) et leurs procédés d'utilisation |
JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
CR20180420A (es) | 2016-02-03 | 2018-12-05 | Amgen Inc | Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t |
SI3411404T1 (sl) | 2016-02-03 | 2023-01-31 | Amgen Research (Munich) Gmbh | Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico |
EP4302782A3 (fr) | 2016-03-15 | 2024-03-27 | Mersana Therapeutics, Inc. | Conjugués anticorps-médicament ciblant napi2b et leurs procédés d'utilisation |
WO2017157305A1 (fr) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Protéines de fusion à fab multispécifiques et leur utilisation |
KR20220004226A (ko) | 2016-03-22 | 2022-01-11 | 바이오노믹스 리미티드 | 항-lgr5 단클론성 항체의 투여 |
JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
KR20230166146A (ko) | 2016-12-16 | 2023-12-06 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물을 사용하여 TTR-관련 질병을 치료하거나 예방하는 방법 |
JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
TWI801377B (zh) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | 治療具有b型肝炎病毒(hbv)感染之個體之方法 |
AR111773A1 (es) | 2017-05-05 | 2019-08-21 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración |
US11866701B2 (en) | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
WO2019100039A1 (fr) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de composant p amyloïde serique et leurs procédés d'utilisation |
EA202091422A1 (ru) | 2017-12-11 | 2020-08-28 | Эмджен Инк. | Способ непрерывного производства продуктов на основе биспецифических антител |
US11597932B2 (en) | 2017-12-21 | 2023-03-07 | Alnylam Pharmaceuticals, Inc. | Chirally-enriched double-stranded RNA agents |
UY38041A (es) | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
US20210301017A1 (en) | 2018-07-30 | 2021-09-30 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
MA53330A (fr) | 2018-08-03 | 2021-06-09 | Amgen Inc | Constructions d'anticorps pour cldn18.2 et cd3 |
JP2021534779A (ja) | 2018-08-27 | 2021-12-16 | アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク | 抗体構築物がプレロードされた凍結保存nk細胞 |
CN112424355A (zh) | 2018-09-18 | 2021-02-26 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
AU2019356564A1 (en) | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
US20220056444A1 (en) | 2018-12-05 | 2022-02-24 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
JP2022515744A (ja) | 2018-12-20 | 2022-02-22 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | Kcnt1関連障害の治療のための組成物及び方法 |
US11116778B2 (en) | 2019-01-15 | 2021-09-14 | Empirico Inc. | Prodrugs of ALOX-15 inhibitors and methods of using the same |
JP2022532652A (ja) | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
TW202045711A (zh) | 2019-06-13 | 2020-12-16 | 美商安進公司 | 生物製品製造中基於生物量之自動灌注控制 |
CA3148591A1 (fr) | 2019-07-26 | 2021-02-04 | Amgen Inc. | Proteines de liaison a un antigene anti-il13 |
EP4013870A1 (fr) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni à sous-unité de protéine ribosomale 25 (rps25) et leurs procédés d'utilisation |
US20220306741A1 (en) | 2019-09-10 | 2022-09-29 | Amgen Inc. | Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity |
WO2021087036A1 (fr) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions d'agents à base d'arni ciblant la huntingtine (htt) et leurs procédés d'utilisation |
CA3156683A1 (fr) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Procede de reduction de la formation d'agregats dans le traitement en aval de molecules de liaison a l'antigene bispecifiques |
US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
IL293824A (en) | 2019-12-13 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them |
CA3164129A1 (fr) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Constructions d'anticorps multispecifique agoniste de cd40 cible par la mesotheline permettant le traitement de tumeurs solides |
EP4081554A1 (fr) | 2019-12-27 | 2022-11-02 | Affimed GmbH | Procédé de production de construction d'anticorps bispécifique fcyriii x cd30 |
WO2021150824A1 (fr) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations |
WO2021154941A1 (fr) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla) |
EP4114947A1 (fr) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de composant c3 du complément et leurs procédés d'utilisation pour le traitement ou la prévention de maladies associées au composant c3 du complément |
EP4118113A1 (fr) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Méthodes de traitement et de prophylaxie du crs chez des patients, comprenant une association d'anticorps bispécifiques se liant à une cellule tumorale du cds x et d'un inhibiteur du tnf alpha ou de l'il-6 |
AU2021240028A1 (en) | 2020-03-19 | 2022-09-15 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
EP4127168A1 (fr) | 2020-03-26 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de coronavirus et leurs procédés d'utilisation |
WO2021206922A1 (fr) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la serine protease 2 transmembranaire (tmprss2) et leurs procédés d'utilisation |
EP4133076A1 (fr) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions arni d'enzyme de conversion de l'angiotensine 2 (eca2) et procédés d'utilisation associés |
CA3181400A1 (fr) | 2020-04-27 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni de l'apolipoproteine e (apoe) et leurs procedes d'utilisation |
WO2021231675A1 (fr) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar d'argininosuccinate synthétase (ass1) |
WO2021231673A1 (fr) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar de la kinase 2 à répétition riche en leucine (lrrk2) |
WO2021231679A1 (fr) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar de la protéine bêta 2 de jonction lacunaire (gjb2) |
WO2021231685A1 (fr) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar de la protéine 1 de type canal transmembranaire (tmc1) |
WO2021231691A1 (fr) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar de rétinoschisine 1 (rs1) |
WO2021231692A1 (fr) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar d'otoferline (otof) |
EP4150078A1 (fr) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar d'argininosuccinate lyase (asl) |
EP4150076A1 (fr) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar de la protéine 2 de liaison méthyl-cpg (mecp2) |
CA3183756A1 (fr) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Constructions de liaison a mageb2 |
JP2023527972A (ja) | 2020-05-29 | 2023-07-03 | アムジエン・インコーポレーテツド | Cd33及びcd3に結合する二重特異性コンストラクトの有害作用軽減投与 |
AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
WO2021252557A1 (fr) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni et leurs procédés d'utilisation pour une administration par inhalation |
JP2023540429A (ja) | 2020-07-10 | 2023-09-25 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | てんかんを治療するための方法及び組成物 |
EP4217489A1 (fr) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de dipeptidyle peptidase 4 (dpp4) et leurs procédés d'utilisation |
JP2023544413A (ja) | 2020-10-05 | 2023-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法 |
US20230365709A1 (en) | 2020-10-08 | 2023-11-16 | Affimed Gmbh | Trispecific binders |
EP4232581A1 (fr) | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Méthodes et compositions pour le traitement de l'hyperoxalurie primaire |
EP4232582A1 (fr) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la mucine 5b (muc5b) et leurs méthodes d'utilisation |
CN116323671A (zh) | 2020-11-06 | 2023-06-23 | 安进公司 | 具有增加的选择性的多靶向性双特异性抗原结合分子 |
TW202225188A (zh) | 2020-11-06 | 2022-07-01 | 德商安美基研究(慕尼黑)公司 | 與cd3結合的多肽構建體 |
CA3199976A1 (fr) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Constructions polypeptidiques se liant selectivement a cldn6 et cd3 |
KR20230098335A (ko) | 2020-11-06 | 2023-07-03 | 암젠 인크 | 클리핑 비율이 감소된 항원 결합 도메인 |
AU2021393417A1 (en) | 2020-12-01 | 2023-06-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
BR112023015761A2 (pt) | 2021-02-12 | 2023-11-07 | Alnylam Pharmaceuticals Inc | Superóxido dismutase 1 (sod1) composições de irna e métodos de uso das mesmas para tratar ou prevenir doenças neurodegenerativas associadas a superóxido dismutase 1 (sod1) |
JP2024509783A (ja) | 2021-02-25 | 2024-03-05 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | プリオンタンパク質(prnp)irna組成物およびその使用方法 |
EP4305169A1 (fr) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de la glycogène synthase kinase 3 alpha (gsk3a) et leurs procédés d'utilisation |
CN117203336A (zh) | 2021-03-29 | 2023-12-08 | 阿尔尼拉姆医药品有限公司 | 亨廷顿蛋白(HTT)iRNA药剂组合物以及其使用方法 |
WO2022212831A1 (fr) | 2021-04-02 | 2022-10-06 | Amgen Inc. | Constructions de liaison à mageb2 |
EP4330396A1 (fr) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Transducteur de signal et activateur de compositions d'arni du facteur de transcription 6 (stat6) et procédés d'utilisation correspondants |
CA3217180A1 (fr) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Molecules de liaison a l'antigene ciblant cd20 et cd22 destinees a etre utilisees dans des maladies proliferatives |
WO2022245583A1 (fr) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de cotransporteur-2 de sodium-glucose (sglt2) et leurs procédés d'utilisation |
EP4341405A1 (fr) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Procédés et compositions pour l'édition médiée par adar |
WO2022256283A2 (fr) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Méthodes de restauration de la fonction protéique par adar |
AU2022283796A1 (en) | 2021-06-04 | 2023-11-09 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
EP4363574A1 (fr) | 2021-06-29 | 2024-05-08 | Korro Bio, Inc. | Procédés et compositions pour édition médiée par adar |
TW202325312A (zh) | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法 |
WO2023007023A1 (fr) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Corps duplex |
WO2023069603A1 (fr) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Procédés et compositions pour perturber l'interaction de la protéine nrf2-keap1 par l'édition d'arn à médiation adar |
WO2023076450A2 (fr) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni de la huntingtine (htt) et leurs procédés d'utilisation |
CA3233696A1 (fr) | 2021-11-03 | 2023-05-11 | Joachim Koch | Liants de cd16a bispecifiques |
CA3237018A1 (fr) | 2021-11-03 | 2023-05-11 | Joachim Koch | Liants de cd16a bispecifiques |
WO2023122762A1 (fr) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation de la transcription génique à l'aide d'oligonucléotides antisens ciblant des arn régulateurs |
WO2023141314A2 (fr) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni d'enzyme de voie de biosynthèse de sulfate d'héparine et leurs méthodes d'utilisation |
WO2023218027A1 (fr) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Molécules bispécifiques multicibles à chaînes multiples de liaison à un antigène à sélectivité accrue |
WO2023240277A2 (fr) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Méthodes de modulation de l'expression de progranuline à l'aide d'oligonucléotides antisens ciblant des arn régulateurs |
WO2024059675A2 (fr) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Composition de stabilisation de molécule bispécifique |
WO2024059165A1 (fr) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation |
WO2024119145A1 (fr) | 2022-12-01 | 2024-06-06 | Camp4 Therapeutics Corporation | Modulation de la transcription du gène syngap1 à l'aide d'oligonucléotides antisens ciblant les arn régulateurs |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5175385A (en) * | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
-
1993
- 1993-06-18 NZ NZ25394393A patent/NZ253943A/en unknown
- 1993-06-18 WO PCT/US1993/005873 patent/WO1994000569A1/fr not_active Application Discontinuation
- 1993-06-18 CA CA 2135313 patent/CA2135313A1/fr not_active Abandoned
- 1993-06-18 AU AU45410/93A patent/AU4541093A/en not_active Abandoned
- 1993-06-18 EP EP93915422A patent/EP0648265A4/fr not_active Withdrawn
- 1993-06-18 JP JP6502483A patent/JPH07508410A/ja not_active Ceased
Non-Patent Citations (5)
Title |
---|
CHOI TK ET AL: "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome [published erratum appears in Nat Genet 1993 Jul;4(3):320]", NAT GENET, JUN 1993, 4 (2) P117-23, UNITED STATES, XP002014859 * |
HADLACZKY G ET AL: "CENTROMERE FORMATION IN MOUSE CELLS COTRANSFORMED WITH HUMAN DNA AND A DOMINANT MARKER GENE", PROC NATL ACAD SCI U S A, 88 (18). 1991. 8106-8110., XP002014858 * |
See also references of WO9400569A1 * |
STRAUSS WM ET AL: "Molecular complementation of a collagen mutation in mammalian cells using yeast artificial chromosomes.", EMBO J, FEB 1992, 11 (2) P417-22, ENGLAND, XP002014856 * |
SU ZZ ET AL: "TRANSFER OF A DOMINANT-ACTING TUMOR-INDUCING ONCOGENE FROM HUMAN PROSTATIC-CARCINOMA CELLS TO CLONED RAT EMBRYO FIBROBLAST CELLS BY DNA-TRANSFECTION", ANTICANCER RESEARCH, 1992, 12, 297-304, XP002014857 * |
Also Published As
Publication number | Publication date |
---|---|
NZ253943A (en) | 1997-01-29 |
WO1994000569A1 (fr) | 1994-01-06 |
JPH07508410A (ja) | 1995-09-21 |
CA2135313A1 (fr) | 1994-01-06 |
EP0648265A1 (fr) | 1995-04-19 |
AU4541093A (en) | 1994-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0648265A4 (fr) | Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure. | |
CA2140638A1 (fr) | Production d'anticorps xenogeniques | |
WO2003084477A3 (fr) | Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations | |
WO2004002417A3 (fr) | Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations | |
WO1998045456A8 (fr) | Sequences d'adn codant pour une 2-desoxyglucose-6-phosphate (2-dog-6-p) phosphatase et servant de marqueur de selection chez les vegetaux | |
LUC00010I1 (fr) | ||
CA2074355A1 (fr) | Plants de mais transgeniques fertiles | |
TWI255853B (en) | Method for modifying chromosomes | |
AU560340B2 (en) | Rennin from recombinant dna | |
WO1997004114A3 (fr) | Sequence adn isolee pouvant servir de zone de regulation dans un gene chimere utilisable pour la transformation des plantes | |
WO2000007430A3 (fr) | Promoteurs de desaturase d'acides gras vegetaux | |
WO1995006128A3 (fr) | Plantes de mais transgeniques fertiles et leurs procedes de production | |
CA2209617A1 (fr) | Additifs pour l'alimentation animale, comportant de la xylanase | |
EP0896063A3 (fr) | Méthode pour la sélection de cellules transformées génétiquement et composés à utiliser dans cette méthode | |
WO1997040183A3 (fr) | Chromosomes artificiels, leurs utilisations et leurs procedes de preparation | |
WO2000040694A3 (fr) | Procedes de modification de la masse organique, de controle de la fertilite, et d'amelioration de la reproduction asexuee chez les plantes | |
WO2000051424A3 (fr) | Modification genetique de cellules somatiques et leurs utilisations | |
AU1156797A (en) | Commercial production of aprotinin in plants | |
EP0334539A3 (fr) | Manipulation génétique | |
WO2003020888A3 (fr) | Sequence d'acide nucleique de la photomorphogenese 1 constitutive (cop1) de zea mays et son utilisation | |
WO1999042589A3 (fr) | Toxines insecticides de photorhabdus | |
HU182395B (en) | Method for growing of corn by watering cultivation | |
KR0132666B1 (en) | Method for controlling cultivation conditions for animal cells | |
DE69023036D1 (de) | Klonierung von Streptomyces avermitilis Genen zur Biosynthese von Avermectin und Verfahren zu ihrer Verwendung. | |
WO2000015772A3 (fr) | Production de proteines recombinantes dans l'urine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: C12N 15/88 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19961021 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19970108 |